{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T22:39:01Z","timestamp":1794523141530,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lab Anim"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1038\/s41684-021-00876-y","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T16:15:57Z","timestamp":1634832957000},"page":"327-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development and characterization of a new swine model of invasive pneumococcal pneumonia"],"prefix":"10.1038","volume":"50","author":[{"given":"Rosanel","family":"Amaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Li Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Motos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7528-9636","authenticated-orcid":false,"given":"Laia","family":"Fernandez-Barat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Aguilera Xiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rigol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6794-6456","authenticated-orcid":false,"given":"Gerard","family":"Frigola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Travierso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pagliara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carbonara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3574-6318","authenticated-orcid":false,"given":"Talitha","family":"Comaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Chiurazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minlan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Arrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Daniel","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Adela","family":"Saco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Rinaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Terraneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Artigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8643-2167","authenticated-orcid":false,"given":"Antoni","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"876_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/thx.2010.143982","volume":"66","author":"C Cilloniz","year":"2011","unstructured":"Cilloniz, C. et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 66, 340\u2013346 (2011).","journal-title":"Thorax"},{"key":"876_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2105\/AJPH.90.2.223","volume":"90","author":"DR Feikin","year":"2000","unstructured":"Feikin, D. R. et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Public Health 90, 223\u2013229 (2000).","journal-title":"Am. J. Public Health"},{"key":"876_CR3","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1007\/s00134-018-5444-x","volume":"44","author":"JP Bedos","year":"2018","unstructured":"Bedos, J. P. et al. Host-pathogen interactions and prognosis of critically ill immunocompetent patients with pneumococcal pneumonia: the nationwide prospective observational STREPTOGENE study. Intensive Care Med. 44, 2162\u20132173 (2018).","journal-title":"Intensive Care Med."},{"key":"876_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fcimb.2016.00098","volume":"6","author":"MR Schroeder","year":"2016","unstructured":"Schroeder, M. R. & Stephens, D. S. Macrolide resistance in Streptococcus pneumoniae. Front. Cell. Infect. Microbiol. 6, 98 (2016).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"876_CR5","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/cid\/cix446","volume":"65","author":"MR Schroeder","year":"2017","unstructured":"Schroeder, M. R. et al. A population-based assessment of the impact of 7- and 13-valent pneumococcal conjugate vaccines on macrolide-resistant invasive pneumococcal disease: emergence and decline of Streptococcus pneumoniae serotype 19A (CC320) with dual macrolide resistance mechanisms. Clin. Infect. Dis. 65, 990\u2013998 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"876_CR6","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/cid\/cix685","volume":"65","author":"P Naucler","year":"2017","unstructured":"Naucler, P. et al. Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations. Clin. Infect. Dis. 65, 1780\u20131789 (2017).","journal-title":"Clin. Infect. Dis."},{"key":"876_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/1469-0691.12518","volume":"20","author":"S Aliberti","year":"2014","unstructured":"Aliberti, S., Mantero, M., Mirsaeidi, M. & Blasi, F. The role of vaccination in preventing pneumococcal disease in adults. Clin. Microbiol. Infect. 20, 52\u201358 (2014).","journal-title":"Clin. Microbiol. Infect."},{"key":"876_CR8","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1128\/JCM.01454-08","volume":"47","author":"A Fenoll","year":"2009","unstructured":"Fenoll, A. et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J. Clin. Microbiol. 47, 1012\u20131020 (2009).","journal-title":"J. Clin. Microbiol."},{"key":"876_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3366-4","volume":"18","author":"J Quah","year":"2018","unstructured":"Quah, J., Jiang, B., Tan, P. C., Siau, C. & Tan, T. Y. Impact of microbial Aetiology on mortality in severe community-acquired pneumonia. BMC Infect. Dis. 18, 451 (2018).","journal-title":"BMC Infect. Dis."},{"key":"876_CR10","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1128\/CMR.00012-08","volume":"21","author":"D Chiavolini","year":"2008","unstructured":"Chiavolini, D., Pozzi, G. & Ricci, S. Animal models of Streptococcus pneumoniae disease. Clin. Microbiol. Rev. 21, 666\u2013685 (2008).","journal-title":"Clin. Microbiol. Rev."},{"key":"876_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1378\/chest.07-0185","volume":"132","author":"CM Luna","year":"2007","unstructured":"Luna, C. M. et al. Experimental severe Pseudomonas aeruginosa pneumonia and antibiotic therapy in piglets receiving mechanical ventilation. Chest 132, 523\u2013531 (2007).","journal-title":"Chest"},{"key":"876_CR12","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1183\/09031936.00176709","volume":"36","author":"P Martinez-Olondris","year":"2010","unstructured":"Martinez-Olondris, P. et al. An experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated piglets. Eur. Respir. J. 36, 901\u2013906 (2010).","journal-title":"Eur. Respir. J."},{"key":"876_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/jac\/28.suppl_C.45","volume":"28","author":"E Azoulay-Dupuis","year":"1991","unstructured":"Azoulay-Dupuis, E., Bedos, J. P., Vallee, E. & Pocidalo, J. J. Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin. J. Antimicrob. Chemother. 28, 45\u201353 (1991).","journal-title":"J. Antimicrob. Chemother."},{"key":"876_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0034-5687(99)00045-6","volume":"116","author":"K Iwasaki","year":"1999","unstructured":"Iwasaki, K. et al. Combined effects of both bacteria and gastric juice on pneumonia in mice. Respir. Physiol. 116, 201\u2013209 (1999).","journal-title":"Respir. Physiol."},{"key":"876_CR15","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1128\/AAC.48.5.1699-1707.2004","volume":"48","author":"D Croisier","year":"2004","unstructured":"Croisier, D. et al. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob. Agents Chemother. 48, 1699\u20131707 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"876_CR16","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1128\/AAC.43.10.2484","volume":"43","author":"L Piroth","year":"1999","unstructured":"Piroth, L. et al. Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob. Agents Chemother. 43, 2484\u20132492 (1999).","journal-title":"Antimicrob. Agents Chemother."},{"key":"876_CR17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1165\/rcmb.2013-0340OC","volume":"50","author":"BD Kraft","year":"2014","unstructured":"Kraft, B. D. et al. Development of a novel preclinical model of pneumococcal pneumonia in nonhuman primates. Am. J. Respir. Cell Mol. Biol. 50, 995\u20131004 (2014).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"876_CR18","doi-asserted-by":"publisher","first-page":"e0166092","DOI":"10.1371\/journal.pone.0166092","volume":"11","author":"LF Reyes","year":"2016","unstructured":"Reyes, L. F. et al. A non-human primate model of severe pneumococcal pneumonia. PLoS One 11, e0166092 (2016).","journal-title":"PLoS One"},{"key":"876_CR19","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1097\/01.CCM.0000147444.58070.72","volume":"32","author":"SC Lim","year":"2004","unstructured":"Lim, S. C. et al. Transient hemodynamic effects of recruitment maneuvers in three experimental models of acute lung injury. Crit. Care Med. 32, 2378\u20132384 (2004).","journal-title":"Crit. Care Med."},{"key":"876_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/cc13812","volume":"18","author":"AP Walden","year":"2014","unstructured":"Walden, A. P. et al. Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. Crit. Care 18, R58 (2014).","journal-title":"Crit. Care"},{"key":"876_CR21","first-page":"PA4553","volume":"54","author":"M Yang","year":"2019","unstructured":"Yang, M. et al. Corticosteroid therapy combined with antibiotics for severe Streptococcus pneumoniae pneumonia in ventilated piglets. Eur. Respir. J. 54, PA4553 (2019).","journal-title":"Eur. Respir. J."},{"key":"876_CR22","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1097\/00003246-200008000-00020","volume":"28","author":"A Torres","year":"2000","unstructured":"Torres, A. et al. Sampling methods for ventilator-associated pneumonia: validation using different histologic and microbiological references. Crit. Care Med. 28, 2799\u20132804 (2000).","journal-title":"Crit. Care Med."},{"key":"876_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/cc10444","volume":"15","author":"C Cilloniz","year":"2011","unstructured":"Cilloniz, C. et al. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit. Care 15, R209 (2011).","journal-title":"Crit. Care"},{"key":"876_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","volume":"39","author":"SC Nicholson","year":"2012","unstructured":"Nicholson, S. C. et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int. J. Antimicrob. Agents 39, 240\u2013246 (2012).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"876_CR25","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1128\/AAC.01386-12","volume":"57","author":"AP MacGowan","year":"2013","unstructured":"MacGowan, A. P., Noel, A. R., Tomaselli, S. & Bowker, K. E. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob. Agents Chemother. 57, 2451\u20132456 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"876_CR26","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1164\/rccm.201502-0212OC","volume":"191","author":"C Cilloniz","year":"2015","unstructured":"Cilloniz, C. et al. The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia. Am. J. Respir. Crit. Care Med. 191, 1265\u20131272 (2015).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"876_CR27","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"LA Mandell","year":"2007","unstructured":"Mandell, L. A. et al. Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44, S27\u2013S72 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"876_CR28","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fimmu.2018.00302","volume":"9","author":"P Zimmermann","year":"2018","unstructured":"Zimmermann, P., Ziesenitz, V. C., Curtis, N. & Ritz, N. The immunomodulatory effects of macrolides\u2014a systematic review of the underlying mechanisms. Front. Immunol. 9, 302 (2018).","journal-title":"Front. Immunol."},{"key":"876_CR29","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1164\/rccm.201701-0104OC","volume":"196","author":"LF Reyes","year":"2017","unstructured":"Reyes, L. F. et al. Severe pneumococcal pneumonia causes acute cardiac toxicity and subsequent cardiac remodeling. Am. J. Respir. Crit. Care Med. 196, 609\u2013620 (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"876_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/cc13939","volume":"18","author":"JA Roberts","year":"2014","unstructured":"Roberts, J. A. & Roberts, D. M. Antibiotic dosing in critically ill patients with septic shock and on continuous renal replacement therapy: can we resolve this problem with pharmacokinetic studies and dosing guidelines? Crit. Care 18, 156 (2014).","journal-title":"Crit. Care"},{"key":"876_CR31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11739-015-1345-y","volume":"11","author":"W So","year":"2016","unstructured":"So, W., Crandon, J. L. & Nicolau, D. P. Poor outcomes of empiric ceftriaxone +\/- azithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus. Intern. Emerg. Med. 11, 545\u2013551 (2016).","journal-title":"Intern. Emerg. Med."},{"key":"876_CR32","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0924-8579(01)00322-3","volume":"17","author":"RC Owens Jr.","year":"2001","unstructured":"Owens, R. C. Jr. et al. Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens. Int. J. Antimicrob. Agents 17, 483\u2013489 (2001).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"876_CR33","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/CCM.0b013e318236efb5","volume":"40","author":"G Li Bassi","year":"2012","unstructured":"Li Bassi, G. et al. Effects of duty cycle and positive end-expiratory pressure on mucus clearance during mechanical ventilation*. Crit. Care Med. 40, 895\u2013902 (2012).","journal-title":"Crit. Care Med."},{"key":"876_CR34","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1152\/jappl.1989.67.6.2556","volume":"67","author":"E D\u2019Angelo","year":"1989","unstructured":"D\u2019Angelo, E. et al. Respiratory mechanics in anesthetized paralyzed humans: effects of flow, volume, and time. J. Appl. Physiol. (1985) 67, 2556\u20132564 (1989).","journal-title":"J. Appl. Physiol. (1985)"},{"key":"876_CR35","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1001\/jama.2009.856","volume":"301","author":"DN Cruz","year":"2009","unstructured":"Cruz, D. N. et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301, 2445\u20132452 (2009).","journal-title":"JAMA"},{"key":"876_CR36","doi-asserted-by":"publisher","first-page":"e620","DOI":"10.1097\/CCM.0000000000000487","volume":"42","author":"G Li Bassi","year":"2014","unstructured":"Li Bassi, G. et al. Gravity predominates over ventilatory pattern in the prevention of ventilator-associated pneumonia. Crit. Care Med. 42, e620\u2013e627 (2014).","journal-title":"Crit. Care Med."},{"key":"876_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0924-8579(98)00087-9","volume":"12","author":"CO Onyeji","year":"1999","unstructured":"Onyeji, C. O. et al. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Int. J. Antimicrob. Agents 12, 107\u2013114 (1999).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"876_CR38","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1152\/jappl.1986.60.2.532","volume":"60","author":"SI Rennard","year":"1986","unstructured":"Rennard, S. I. et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. (1985) 60, 532\u2013538 (1986).","journal-title":"J. Appl. Physiol. (1985)"},{"key":"876_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1001\/jama.279.2.125","volume":"279","author":"SL Preston","year":"1998","unstructured":"Preston, S. L. et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279, 125\u2013129 (1998).","journal-title":"JAMA"}],"container-title":["Lab Animal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41684-021-00876-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41684-021-00876-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41684-021-00876-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T11:19:01Z","timestamp":1744111141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41684-021-00876-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["876"],"URL":"https:\/\/doi.org\/10.1038\/s41684-021-00876-y","relation":{},"ISSN":["0093-7355","1548-4475"],"issn-type":[{"value":"0093-7355","type":"print"},{"value":"1548-4475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,21]]},"assertion":[{"value":"16 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.T. has received grants from MedImmune, Cubist, Bayer, Theravance and Polyphor and personal fees as an advisory board member from Bayer, Roche, The Medicines CO and Curetis. He has received personal fees as a member of the speaker\u2019s bureau from GSK, Pfizer, Astra Zeneca and Biotest Advisory Board, outside the submitted work. None of the other authors have any competing interests with the current publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}